Never before have we faced a crisis of this magnitude. COVID-19 affects our health, our economy and life as we know it.

Coronavirus is impacting you, me, people we know — everybody.

The main focus of Garvan's COVID-19 research is to keep individuals infected with coronavirus out of critical care. Today, right now, we are developing targeted interventions to stop severe COVID-19 through our antibody, immunology and genomics research.

But we need your help. Please donate.

Your donation directly supports Garvan's COVID-19 projects. This means we can pursue very promising lines of antibody research, scrutinise the genome of the virus, and equip our labs to test and scale up our findings. 
Donations over $2 are tax deductible.

Donate another way

PayPal Logo
Call us on:
1300 73 66 77

Garvan's COVID-19 research

Garvan is using its expertise in antibodies and genomics to do three things:

  • To try and stop the spread of COVID-19 infection
  • To stop people that are infected needing to be hospitalised, or placed in ICU
  • And ultimately: to decrease the mortality rate of COVID-19.

Our approach involves multiple avenues — because there will be more than one answer.

We're investigating genetically engineered antibodies, and undertaking multiple immune genomic analyses. This genomics focus helps us trace the evolution & changes of the virus, and uncover which genes are key for protection and which are indicated for severe COVID-19 symptoms.

A fast-track way to reduce the number of COVID-19 patients needing ICU is to create targeted antibodies in the lab.

These human monoclonal antibodies are hundreds of times more efficacious than standard chemical drugs. Their success rate is higher; they can also be produced at scale and quickly tested for safety. And: they provide immediate immunity for a period of time.

These antibodies bypass the need for a vaccine and could be given to provide immediate immunity, both as treatment and prevention, to at-risk individuals.  We are now optimising these antibodies, then we 'll move to clinical trials.